Nicergoline

Research use only, not for human use.

Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins.

Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins.(In Vitro):Nicergoline (0.3-30 μM; 24 h) attenuates activated microglia- and astrocytes-induced neuronal cell death.Nicergoline (0.3-30 μM; 48 h) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.(In Vivo):Nicergoline (10 mg/kg; i.v. once daily for 60 d) improves impaired neurogenesis and cognitive competence in mice with Alzheimer's disease.Nicergoline (10 mg/kg; i.v. once daily for 60 d) inhibits apoptosis, inflammation and oxidative stress in hippocampal cells, and regulates the activity of hippocampal cells through the PI3K/AKT signaling pathway in mice.

Nicergoline (0.3-30 μM; 24 h) attenuates activated microglia- and astrocytes-induced neuronal cell death.Nicergoline (0.3-30 μM; 48 h) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.

Nicergoline (10 mg/kg; i.v. once daily for 60 d) improves impaired neurogenesis and cognitive competence in mice with Alzheimer's disease.Nicergoline (10 mg/kg; i.v. once daily for 60 d) inhibits apoptosis, inflammation and oxidative stress in hippocampal cells, and regulates the activity of hippocampal cells through the PI3K/AKT signaling pathway in mice. Animal Model:3×Tg-AD mice (male, 28-35 g, 6 weeks) with the Alzheimer's disease Dosage:10 mg/kg Administration:I.v. once daily for 60 days Result:Improved neurogenesis and cognitive competence.Decreased the degree of dementia.Downregulated pathogenic Aβ-42 and -40 peptides and APP in the hippocampi.Increased Levels of the neuroprotective forkhead box protein P2 (Foxp2), Src homology 2-containing inositol phosphatase (SxIP) and end-binding proteins (EB) in the hippocampi.Exhibited marked differences in the dispersion of the pyramidal cell layer between the nicergoline-treated and control groups.

Nicergoline, Nicotergoline, Nimergoline, Sermion

Endocrinology/Hormones

Adrenergic Receptor

Adrenergic Receptor

Neurological Disease

——

27848-84-6

484.39

C24H26BrN3O3

>98% (HPLC)

Soluble in DMSO

O=C(C1=CC(Br)=CN=C1)OC[C@H](C[C@]23OC)CN(C)[C@]3([H])CC4=CN(C)C5=C4C2=CC=C5

[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinoline-9-yl]methyl 5-bromopyridine-3-carboxylate

(-20℃)

With Ice Pack

≥ 2 years